Right orbitofrontal cortex rTMS targets anxiety, not depressive, symptoms in first-episode schizophrenia

Key Points

• Anxiety symptoms showed significant reduction in patients receiving rTMS treatment.
• Patients experienced a notable decrease in anxiety symptoms by 30% after rTMS over eight weeks.
• Analysis of treatment responses in first-episode schizophrenia patients utilizing rTMS was conducted.
• Findings support the potential of rTMS for targeting anxiety specifically, indicating further exploration is needed.